Europe Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030

The Europe thyroid cancer diagnostics market is projected to register a substantial CAGR of 5.2% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation: 
Europe Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group (30-65, 65 and Above, 21-29, Below 21), End Users (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, and the Rest of Europe) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the Europe thyroid cancer diagnostics market are:
• Rising incidence and prevalence of thyroid nodules & cancer
• Rising thyroid cancer diagnostic tests rise in product approvals
• Rise in healthcare expenditure for cancer diagnosis and treatment

Market Players:

Some of the major players operating in the Europe thyroid cancer diagnostics market are:

• FUJIFILM Holdings Corporation
• F. Hoffmann-La Roche Ltd
• Quest Diagnostics Incorporated
• Illumina
• Koninklijke Philips N.V.
• Thermo Fisher Scientific Inc.
• Siemens Healthcare GmbH 
• Abbott
• General Electric Company
• BD
• QIAGEN
• DIASORIN S.P.A.
• Merck KGaA
• Hologic
• Myriad Genetics Inc.
• BIOMERIEUX
• FONAR Corp.
• MinFound Medical Systems Co., Ltd
• Medonica Co. LTD